Intech Investment Management LLC Purchases 73,021 Shares of Natera, Inc. $NTRA

Key Points

• Intech Investment Management LLC significantly increased its stake in Natera, Inc. by 591.4%, acquiring an additional 73,021 shares, bringing its total ownership to 85,369 shares valued at approximately $12.07 million.
• Multiple institutional investors, including Price T Rowe Associates Inc. and UBS AM, have also ramped up their investments in Natera, with the company now having around 99.90% of its shares owned by institutional investors.
• Natera's latest earnings report indicated a revenue of $546.60 million, exceeding expectations, but it reported an EPS of ($0.74), missing analysts' estimates, reflecting challenges despite a 32.2% year-over-year revenue increase.

Intech Investment Management LLC increased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 591.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,369 shares of the medical research company's stock after purchasing an additional 73,021 shares during the period. Intech Investment Management LLC owned 0.06% of Natera worth $12,072,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD boosted its position in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. Nuveen LLC purchased a new position in shares of Natera in the 1st quarter worth $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock worth $177,298,000 after buying an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after buying an additional 660,538 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Natera by 8,233.5% in the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after buying an additional 393,149 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Stock Performance

NASDAQ NTRA opened at $169.79 on Thursday. The company has a market capitalization of $23.30 billion, a price-to-earnings ratio of -88.90 and a beta of 1.68. The company's 50-day simple moving average is $154.79 and its two-hundred day simple moving average is $153.98. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other news, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. The trade was a 34.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total transaction of $500,310.00. Following the completion of the transaction, the insider directly owned 130,205 shares in the company, valued at approximately $21,714,287.85. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,423 shares of company stock worth $8,459,656. 5.63% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent research reports. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research note on Monday, July 28th. Barclays reissued an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Cowen reiterated a "buy" rating on shares of Natera in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.